CKCassandra Kelly-Cirino

Cassandra Kelly-Cirino

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cassandra Kelly-Cirino has a total of 256 co-authors. Here are the top co-authors by number of shared publications:

  • Christina Egan

    Wadsworth Center, New York State Department of Health, 120 New Scotland Avenue, Albany, NY, 12208, USA

    7 shared publications
  • Laura T Mazzola

    Emerging Threats Programme, Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland

    6 shared publications
  • Devy M. Emperador

    FIND, Geneva, Switzerland; Institute of Global Health, University of Geneva, Geneva, Switzerland

    5 shared publications
  • Stephen W. Davis

    Biodefense Laboratory, Wadsworth Center, New York State Department of Health, Albany, New York 12208

    4 shared publications
  • Jill Taylor

    Divisions of Infectious Disease and Molecular Medicine, Wadsworth Center, New York State Department of Health, Albany, New York 12201,1 California Animal Health and Food Safety Laboratory, School of Veterinary Medicine, University of California, Davis, California 95616,2 Departments of Clinical Laboratories, Medicine, and Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 100213

    3 shared publications
  • Patricia S. Curry

    DNA Genotek, Ottawa, Ontario, Canada

    3 shared publications

Latest Publications

  • Open Access

    Establishment of a Lassa Fever Specimen Biobank in Nigeria

    by Hanesh F. Chi, Johnson Etafo, Fritz Fonkeng, Gbenga-Ayeni Bosede Olufunke, Ronke Ireneh, Chukwuyem Abejegah, Sampson Owhin, Stella Somiari, Aurélia Vessière, Daniel G. Bausch, et al.

    : Despite being a dangerous disease found across West Africa, with occasional cases imported elsewhere, few medical countermeasures for Lassa fever are available, with no vaccine or validated treatment, and limited regulatory-approved diagnostics. Scientific research on the Lassa virus (LASV) is needed to accelerate the development of such tools but is dependent on access to high-quality biological samples. To meet this need, we have established a well-curated biobank to prospectively collect, process, and store high-quality, well-characterized clinical specimens from patients with Lassa fever at the Federal Medical Center Owo (FMCO) in Nigeria. Patients presenting to FMCO with symptoms of Lassa fever were tested for LASV by polymerase chain reaction and screened for eligibility. Samples of whole blood, plasma, and serum were collected at baseline, and at 4- and 8-weeks post-baseline from LASV-positive (LASV+) participants. Of 197 participants enrolled, 99 were LASV+ and 98 LASV-negative. In total, 3,599 sample aliquots were stored, comprised of 264 whole blood, 1,572 serum, and 1,763 plasma samples. The Lassa fever biobank now provides support for scientific research, including the evaluation of diagnostics and biomarkers, as well as the development and validation of other medical countermeasures for the detection, prevention, and control of Lassa fever. Processes for accessing samples are described.


  • Open Access

    A call to bridge the diagnostic gap: diagnostic solutions for neonatal sepsis in low- and middle-income countries

    by Birgitta Gleeson, Cecilia Ferreyra, Kara Palamountain, Shevin T Jacob, Naomi Spotswood, Niranjan Kissoon, Yasir Bin Nisar, Felicity Fitzgerald, Sarah Murless-Collins, Uduak Okomo, et al.


  • Open Access

    Use of Measles and Rubella Rapid Diagnostic Tests to Improve Case Detection and Targeting of Vaccinations

    by Audrey Rachlin, Lee M. Hampton, Paul A. Rota, Mick N. Mulders, Mark Papania, James L. Goodson, L. Kendall Krause, Matt Hanson, Jennifer Osborn, Cassandra Kelly-Cirino, et al.

    Efforts to control and eliminate measles and rubella are aided by high-quality surveillance data—supported by laboratory confirmation—to guide decision-making on routine immunization strategies and locations for conducting preventive supplementary immunization activities (SIAs) and outbreak response. Important developments in rapid diagnostic tests (RDTs) for measles and rubella present new opportunities for the global measles and rubella surveillance program to greatly improve the ability to rapidly detect and respond to outbreaks. Here, we review the status of RDTs for measles and rubella Immunoglobulin M (IgM) testing, as well as ongoing questions and challenges regarding the operational use and deployment of RDTs as part of global measles and rubella surveillance. Efforts to develop IgM RDTs that can be produced at scale are underway. Once validated RDTs are available, clear information on the benefits, challenges, and costs of their implementation will be critical for shaping deployment guidance and informing country plans for sustainably deploying such tests. The wide availability of RDTs could provide new programmatic options for measles and rubella elimination efforts, potentially enabling improvements and flexibility for testing, surveillance, and vaccination.


  • Open Access

    Comparative Evaluation of Select Serological Assays for Zika Virus Using Blinded Reference Panels

    by Devy M. Emperador, Mars Stone, Eduard Grebe, Camille Escadafal, Honey Dave, Eve Lackritz, Cassandra Kelly-Cirino, Ingrid Rabe, Diana P. Rojas, Michael P. Busch, et al.

    In response to the 2015 Zika virus (ZIKV) epidemic that occurred in Brazil, numerous commercial serological assays have been developed for clinical and research applications. Diagnosis of recent infection in pregnant women remains challenging. Having standardized, comparative studies of ZIKV tests is important for implementing optimal diagnostic testing and disease surveillance. This is especially important for serology tests used to detect ZIKV infection given that antibodies against ZIKV can cross-react with other arboviruses in the same virus family, such as dengue virus (DENV), yellow fever virus (YFV) and West Nile virus (WNV). We looked at the sensitivity and specificity of tests detecting ZIKV antibodies (IgM, IgG) from multiple manufacturers using panels of samples previously collected with known exposure to ZIKV and other arboviruses. We found that performance of the IgM tests was highly variable, with only one test (Inbios 2.0 IgM capture ELISA) having both high sensitivity and specificity. All IgG tests showed good sensitivity; however, specificity was highly variable, with some assays giving false-positive results on samples infected by another flavivirus. Overall, the results confirmed that accurate ZIKV antibody testing is challenging, especially in specimens from regions endemic for multiple other flaviviruses, and highlight the importance of available and suitable reference samples to evaluate ZIKV diagnostics.


  • Open Access

    Impact of a package of diagnostic tools, clinical algorithm, and training and communication on outpatient acute fever case management in low- and middle-income countries: protocol for a randomized controlled trial

    by Olawale Salami, Philip Horgan, Catrin E. Moore, Abhishek Giri, Asadu Sserwanga, Ashish Pathak, Buddha Basnyat, Francois Kiemde, Frank Smithuis, Freddy Kitutu, et al.

    Background: The management of acute febrile illnesses places a heavy burden on clinical services in many low- and middle-income countries (LMICs). Bacterial and viral aetiologies of acute fevers are often clinically indistinguishable and, in the absence of diagnostic tests, the ‘just-in-case’ use of antibiotics by many health workers has become common practice, which has an impact on drug-resistant infections. Our study aims to answer the following question: in patients with undifferentiated febrile illness presenting to outpatient clinics/peripheral health centres in LMICs, can we demonstrate an improvement in clinical outcomes and reduce unnecessary antibiotic prescription over current practice by using a combination of simple, accurate diagnostic tests, clinical algorithms, and training and communication (intervention package)? Methods: We designed a randomized, controlled clinical trial to evaluate the impact of our intervention package on clinical outcomes and antibiotic prescription rates in acute febrile illnesses. Available, point-of-care, pathogen-specific and non-pathogen specific (host markers), rapid diagnostic tests (RDTs) included in the intervention package were selected based on pre-defined criteria. Nine clinical study sites in six countries (Burkina Faso, Ghana, India, Myanmar, Nepal and Uganda), which represent heterogeneous outpatient care settings, were selected. We considered the expected seasonal variations in the incidence of acute febrile illnesses across all the sites by ensuring a recruitment period of 12 months. A master protocol was developed and adapted for country-specific ethical submissions. Diagnostic algorithms and choice of RDTs acknowledged current data on aetiologies of acute febrile illnesses in each country. We included a qualitative evaluation of drivers and/or deterrents of uptake of new diagnostics and antibiotic use for acute febrile illnesses. Sample size estimations were based on historical site data of antibiotic prescription practices for malarial and non-malarial acute fevers. Overall, 9 semi-independent studies will enrol a minimum of 21,876 patients and an aggregate data meta-analysis will be conducted on completion. Discussion: This study is expected to generate vital evidence needed to inform policy decisions on the role of rapid diagnostic tests in the clinical management of acute febrile illnesses, with a view to controlling the rise of antimicrobial resistance in LMICs. Trial registration: Clinicaltrials.gov NCT04081051. Registered on 6 September 2019. Protocol version 1.4 dated 20 December 2019


  • Open Access

    Impact of a package of diagnostic tools, clinical algorithm, and training and communication on outpatient acute fever case management in low- and middle-income countries: protocol for a randomized controlled trial

    by Olawale Salami, Philip Horgan, Catrin E Moore, Abhishek Giri, Asadu Sserwanga, Ashish Pathak, Buddha Basnyat, Francois Kiemde, Frank Smithuis, Freddy Kitutu, et al.

    Background. The management of acute febrile illnesses places a heavy burden on clinical services in many low- and middle-income countries (LMICs). Bacterial and viral aetiologies of acute fevers are often clinically indistinguishable and, in the absence of diagnostic tests, the ‘just-in-case’ use of antibiotics by many health workers has become common practice, which has an impact on drug-resistant infections.Our study aims to answer the following question: in patients with undifferentiated febrile illness presenting to outpatient clinics/peripheral health centres in LMICs, can we demonstrate an improvement in clinical outcomes and reduce unnecessary antibiotic prescription over current practice by using a combination of simple, accurate diagnostic tests, clinical algorithms, and training and communication (intervention package)? Methods. We designed a randomized, controlled clinical trial to evaluate the impact of our intervention package on clinical outcomes and antibiotic prescription rates in acute febrile illnesses. Available, point-of-care, pathogen-specific and non-pathogen specific (host markers), rapid diagnostic tests (RDTs) included in the intervention package were selected based on pre-defined criteria. Nine clinical study sites in six countries (Burkina Faso, Ghana, India, Myanmar, Nepal and Uganda), which represent heterogeneous outpatient care settings, were selected. We considered the expected seasonal variations in the incidence of acute febrile illnesses across all the sites by ensuring a recruitment period of 12 months. A master protocol was developed and adapted for country-specific ethical submissions. Diagnostic algorithms and choice of RDTs acknowledged current data on aetiologies of acute febrile illnesses in each country. We included a qualitative evaluation of drivers and/or deterrents of uptake of new diagnostics and antibiotic use for acute febrile illnesses. Sample size estimations were based on historical site data of antibiotic prescription practices for malarial and non-malarial acute fevers. Overall, 9 semi-independent studies will enrol a minimum of 21,876 patients and an aggregate data meta-analysis will be conducted on completion. Discussion. This study is expected to generate vital evidence needed to inform policy decisions on the role of rapid diagnostic tests in the clinical management of acute febrile illnesses, with a view to controlling the rise of antimicrobial resistance in LMICs. Trial registration: Clinicaltrials.gov, identifier NCT04081051, registered 06 SEP 2019.Protocol version 1.4 Dated 20 December 2019

  • Open Access

    An open-source molecular diagnostic platform approach for outbreak and epidemic preparedness

    by Devy M. Emperador, Laura T. Mazzola, Cassandra Kelly-Cirino

    Background: Diagnostic development for outbreak pathogens has typically followed a disease-specific reactive rather than proactive response. Given the diversity of outbreak pathogens, particularly those prioritised by the World Health Organization Research and Development Blueprint, a more flexible and proactive approach to epidemic preparedness is needed to expand access to critical molecular diagnostic tests in peripheral and resource-constrained deployment settings. Objective: New and more sustainable directives are needed to spur the development of high-quality products, particularly for epidemics more often found in low- and middle-income countries. To leverage and de-risk the development process, we present the benefits and challenges of an open-source business model for co-development of molecular diagnostic tests for decentralised settings. Methods: We identify key outbreak pathogens that are available only for testing in high infrastructure laboratories and compare in-country installed base platforms that could be leveraged for menu expansion. Key strengths and challenges for development are highlighted for both platform and assay developers, with discussion of how to leverage and de-risk the process through an open-source development model. Results: Depending on the specific partner strengths, options for partnership roles are presented. The proposed open-source business model addresses the particular challenges in the detection of outbreak- and epidemic-prone pathogens in low- and middle-income countries, reduces development and deployment risks to support outbreak response, strengthens diagnostic capacity and creates a viable market for product developers. Conclusion: We hope this model for a collaborative and open-source approach for molecular diagnostics serves to encourage stakeholders to consider co-development partnerships to improve outbreak preparedness and epidemic/pandemic response.


  • Open Access

    Comparative performance study of three Ebola rapid diagnostic tests in Guinea

    by Zelda Moran, William Rodriguez, Doré Ahmadou, Barré Soropogui, N’ Faly Magassouba, Cassandra Kelly-Cirino, Yanis Ben Amor

    Background: The 2014/15 Ebola outbreak in West Africa resulted in 11,000 deaths and massive strain on local health systems, and the ongoing outbreak in Democratic Republic of Congo has afflicted more than 3000 people. Accurate, rapid Ebola diagnostics suitable for field deployment would enable prompt identification and effective response to future outbreaks, yet remain largely unavailable. The purpose of this study was to assess the accuracy of three novel rapid diagnostic tests (RDTs): an Ebola, an Ebola-Malaria, and a Fever Panel test that includes Ebola, all from a single manufacturer. Methods: We evaluated the three RDTs in 109 Ebola-positive and 96 Ebola-negative stored serum samples collected during the outbreak in Guinea in 2014/15, and tested by real-time polymerase chain reaction (RT-PCR). Sensitivity, specificity, and overall percent agreement were calculated for each RDT using RT-PCR as a reference standard, stratified by Ct value ranges. Results: All tests performed with high accuracy on samples with low Ct value (high viral load). The Fever Panel test performed with the highest accuracy, with a sensitivity of 89.9% and specificity of 90.6%. The Ebola and Ebola-Malaria tests performed comparably to each other: sensitivity was 77.1 and 78% respectively, and specificity was 91.7% for the Ebola test and 95.8% for the Ebola-Malaria test. Conclusions: This study evaluated the accuracy of three novel rapid diagnostic tests for Ebola. The tests may have significant public health relevance, particularly the Fever Panel test, which detects seven pathogens including Ebola. Given limitations to the study resulting from uncertain sample quality, further evaluation is warranted. All tests performed with highest accuracy on samples with low Ct value (high viral load), and the data presented here suggests that these RDTs may be useful for point-of-care diagnosis of cases in the context of an outbreak. Restrictions to their use in non-severe Ebola cases or for longitudinal monitoring, when viral loads are lower, may be appropriate. Highlighting the challenge in developing and evaluating Ebola RDTs, there were concerns regarding sample integrity and reference testing, and there is a need for additional research to validate these assays.


  • Top Cited Papers
    Open Access

    Diagnosing sexually transmitted infections in resource‐constrained settings: challenges and ways forward

    by Teodora Ec Wi, Francis J Ndowa, Cecilia Ferreyra, Cassandra Kelly‐Cirino, Melanie M Taylor, Igor Toskin, James Kiarie, Nancy Santesso, Magnus Unemo

    Introduction: Sexually transmitted infections (STIs) remain prevalent and are increasing in several populations. Appropriate STI diagnosis is crucial to prevent the transmission and sequelae of untreated infection. We reviewed the diagnostic accuracy of syndromic case management and existing point‐of‐care tests (POCTs), including those in the pipeline, to diagnose STIs in resource‐constrained settings.Methods: We prioritized updating the systematic review and meta‐analysis of the diagnostic accuracy of vaginal discharge from 2001 to 2015 to include studies until 2018. We calculated the absolute effects of different vaginal flowcharts and the diagnostic performance of POCTs on important outcomes. We searched the peer‐reviewed literature for previously conducted systematic reviews and articles from 1990 to 2018 on the diagnostic accuracy of syndromic management of vaginal and urethral discharge, genital ulcer and anorectal infections. We conducted literature reviews from 2000 to 2018 on the existing POCTs and those in the pipeline.Results and discussions: The diagnostic accuracy of urethral discharge and genital ulcer disease syndromes is relatively adequate. Asymptomatic Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections limit the use of vaginal discharge and anorectal syndromes. The pooled diagnostic accuracy of vaginal syndromic case management for CT/NG is low, resulting in high numbers of overtreatment and missed treatment. The absolute effect of POCTs was reduced overtreatment and missed treatment. Findings of the reviews on syndromic case management underscored the need for low‐cost and accurate POCTs for the identification, first, of CT/NG, and, second, of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) and NG and MG resistance/susceptibility testing. Near‐patient POCT molecular assays for CT/NG/TV are commercially available. The prices of these POCTs remain the barrier for uptake in resource‐constrained settings. This is driving the development of lower cost solutions.Conclusions: The WHO syndromic case management guidelines should be updated to raise the quality of STI management through the integration of laboratory tests. STI screening strategies are needed to address asymptomatic STIs. POCTs that are accurate, rapid, simple and affordable are urgently needed in resource‐constrained settings to support the uptake of aetiological diagnosis and treatment.


  • Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: A meeting report

    by A. Wilder-Smith, P.G. Smith, R. Luo, C. Kelly-Cirino, D. Curry, H. Larson, A. Durbin, M. Chu, P. Tharmaphornpilas, L.C. Ng, et al.